



7018 Owensmouth Ave. Suite 103  
 Canoga Park, CA 91303  
 Tell : (818) 710-1281  
 Fax : (818) 936-0121  
 Email: Info@immunospec.com  
[www.immunospec.com](http://www.immunospec.com)

## Coagulation Control Plasma 3

(Highly Elevated Coagulation Time)

**REF**

Catalog No. S12-749

**IVD**

For In Vitro Diagnostic Use Only

### INTENDED USE

The Immunospec **Coagulation Control Plasma 3** is intended for use for quality assurance of *in vitro* diagnostic coagulation tests<sup>(1-3)</sup>. The reagent is suitable for use as a **highly elevated coagulation time** control in the one-stage prothrombin time (PT) assay and in the activated partial thromboplastin time (APTT) assay.

### REAGENT

The Immunospec **Coagulation Control Plasma 3** is a lyophilized preparation of human plasma containing buffers and stabilizers.

### PRECAUTIONS

1. Do not ingest.
2. Avoid contact with skin, eyes or clothing.
3. **WARNING: POTENTIAL BIOHAZARDOUS MATERIAL**

The source material for this product has been tested and found negative for the presence of HIV and HCV antibodies as well as Hepatitis B Surface Antigen by approved test methods. However, no known test method can offer assurance that products derived from human blood are free of infectious agents. Therefore, handle this material observing the same safety precautions employed when handling any potentially infectious material.

### REAGENT PREPARATION

1. Reconstitute the Immunospec **Coagulation Control Plasma 3** with 1.0 ml. of purified water.
2. Replace the stopper and gently mix the vial to thoroughly disperse the contents. Let stand at room temperature for no less than 30 minutes before use to assure complete rehydration of the contents.

### STORAGE AND STABILITY

The reconstituted plasma control is stable for 6 hours when stored refrigerated (2 to 8°C) in the original container.

### PROCEDURE

The reconstituted Immunospec **Coagulation Control Plasma 3** is tested in the same manner as freshly drawn citrated patient plasma in prothrombin time test and activated partial thromboplastin times. Refer to the appropriate product inserts for test specific instructions.

### LIMITATIONS

The Immunospec **Coagulation Control Plasma 3**, when properly used, is subject to the limitations of the assay system employed. Results outside of the reference range may indicate product deterioration or problems with one or more components of the test system.

### PERFORMANCE CHARACTERISTICS

Influences such as reagent type, ISI value of the PT reagent, methodology, instrumentation and technique contribute to variation in test results. Each laboratory should establish its own acceptance ranges with

each new lot of plasma control. The Immunospec **Coagulation Control Plasma 3** will typically yield results within the range specified in the following table, for most PT and APTT assays.

Coagulation Test	Normal Clotting Time (seconds)
Prothrombin Time (PT) ISI 1.0 – 1.4	43 – 72
Prothrombin Time (PT) ISI 1.8 – 2.0	26 – 42
Activated Partial Thromboplastin Time (APTT)	61 – 85

The coefficient of variation (CV) for prothrombin time (PT) and activated partial thromboplastin time (APTT) tests performed on the Immunospec **Coagulation Control Plasma 3** has been shown to be less than 5 % in intra-laboratory studies. However, precision characteristics will vary depending on the instrumentation and reagent system used.

The results are shown in the following table:

	PT Precision	APTT Precision
Within-run (n=20)	± 3.5 % CV	± 2.3 % CV
Day to Day (5 days)	± 4.5 % CV	± 3.9 % CV

### REFERENCES

1. Miale JB, Laboratory Medicine, Hematology, CN Mosbey Co., St Louis (1977)
2. Sirridge MS, Laboratory Evaluation of Hemostasis, Lea & Febiger, Philadelphia (1967)
3. Loeliger EA, Hemker HA, Thromb Diathes Haemorrh 40 p359 (1969)

**EC REP**

European Authorized Representative:

Cepatuier+O, Esdoornlaan 13, 3951DB Maarn  
 . The Netherlands. Tel.: +31 (0)6.516.536.26



Manufacturer:

IMMUNOSPEC CORPORATION  
 7018 Owensmouth Ave., Suite 103  
 Canoga Park, CA 91303  
 Tell : (818) 710-1281

PS12-749  
 Revision No: 3.2  
 Revision date: 02/ 10